Here's is my quick form strategy for investing during an Obama presidency:

Health care stocks should perform well under an Obama administration. It has been made clear that within the next four years our healthcare system shall be taking on a radical new form. There is certain to be a massive infusion of new money into the sector. I would hasten to clarify that pharmaceutical stocks might not be the angle that you want to play here. I would lean more towards hospitals and long-term care providers. Check out this analysis from Kiplinger, to get yourself started.

Next, I'd be looking at infrastructure plays. I'd focus on materials, procurement, and construction, as they relate to roads, tunnels and bridges. This play will be more dangerous in the near term, as these types of expenditures will be more dependent on governmental budgetary processes, rather than executive edict. Jim Cramer recently offered some input about infrastructure. You might want to check out his suggestions. Then, you can find information about building an infrastructure position at TheStreet.com. Additionally, here's a great list of infrastructure companies which has been provided by Seeking Alpha.

To me, perhaps the most important investment angle to play through the next administration will be alternative energy stocks. I expect that there will be a great deal of money moving in there. Ethanol is said to be a sure thing. I myself am not so positive about that. Oh, we can be sure that there will be plenty of ethanol to go around. However, I don't see much financial return in it at the investor's level. I lean towards solar plays, and to a lesser degree, I like wind power. You can get a good feel for alternative energy direction by reviewing The Pickens Plan. There is no shortage of companies to invest in if you're looking for alternative energy plays. You can easily start your stock picking hunt by checking out the companies which are included in the Wilderhill Clean Energy Index.

As always, stock portfolio success begins with good research. Hopefully, I've given you some quality leads to get started with. When all is said and done, history clearly shows that the markets flourish under administrations controlled by the democrats. Let's hope to God that this time around won't be the exception.

Leo Fasciocco, who specializes in stocks that have shown technical "breakouts," turns to Abbott Labs (NYSE: ABT) as the latest featured stock in his top notch Ticker Tape Digest.

"Abbott has been acting strong depite market weakness, indicating that money moving into ABT, perhaps as a defensive play.

"ABT has a low beta of 0.14 versus the S&P 500's 1.00. That would indicate that ABT is a low risk play. In any case, the stock is set up nicely for a breakout from an eight-week flat base. With good earnings coming this year, we suggest accumulation of the shares.

"Abbott's products include prescription drugs, coronary and carotid stents, and nutritional liquids for infants and adults.

"The stock's long-term chart shows ABT 'knocking on the door' of a new high. It just needs to get over 61.09. If it can do that it could well draw in more buying.

"ABT is acting strong and is a good spot for institutional money to move into in a difficult market. We suggest accumulation of a partial stake in ABT with further buying to be done on a move over 60.

"Overall, we see ABT as a conservative play with low downside risk. We are targeting the stock for a move to 70 within the next few months."

Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.

This post is part of a series in which TheStockAdvisors.com asked financial experts to name their top stock pick if McCain or if Obama wins the election.

"Should Obama win the election, we would look towards select sub-sectors of health care; one stock we would expect to benefit is health supply distributor, Cardinal Health (NYSE: CAH)," explains Kelley Wright, editor of the blue chip Investment Quality Trends.

"A President Obama will have to make good on his promise to deliver better health care. While this could create havoc for the pharmaceutical producers, drug therapies and medical supplies will have to be delivered.

"The 800lb. gorilla in the supply and distribution space is Cardinal Health. Cardinal is a global company whose distribution businesses consolidate pharmaceuticals and medical products from thousands of manufacturers into site-specific deliveries to retail pharmacies, hospitals, physician's offices, surgery centers and alternate care facilities.

"The company has recently taken steps to increase the percentage of cash flow into dividends and share repurchases to enhance shareholder value.

"The blue chip stocks that we recommend are chosen for the exemplary long-term dividend growth, a P/E ratio of 15 or less, a payout ratio of 50% or less, debt of 50% or less, and technical characteristics on the daily and weekly charts that suggests the potential for imminent capital appreciation.

"While the current dividend yield on Cardinal Health is comparatively low at around 1.0%, the upside potential for capital appreciation is quite large."

Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.

This post is part of a series in which TheStockAdvisors.com asked financial experts to name their top stock pick if McCain or if Obama wins the election.

"If Obama gets elected I expect him to pay great attention to domestic health care issues, in which case generic pharmaceutical companies should benefit; India-based Dr. Reddy's Laboratories (NYSE: RDY) will fare very well under such a scenario," says global stock specialist Yiannis Mostrous in The Silk Road Investor.

"The two main prospects for the company are its participation in the generic Allegra business, which could generate about $20 million in profits.

"As Dr. Reddy's has increased its U.S. pipeline filings to 60 Abbreviated New Drug Applications (ANDAs) pending approval, its U.S. business should be back on track soon.

"The second prospect is a potential merger and acquisition spree among the Indian pharmaceutical companies in an effort to face competition more effectively.

"A viable merger will allow companies to reduce research and development (R&D), as well as administrative costs, since there's an overlap when it comes to filing for the approval of similar products.

The day may have closed down in negative territory for stocks, but even watching it all day didn't give one any major feel for the market's direction into the close. Today's PCE Inflation index came in at +4.1%, although traders have discounted this data as energy prices and even some food prices have started coming down from the May to June highs. Oil put in a serious drop to briefly under $120 and now traders are calling for lower levels rather than higher. You could throw up literally 5 issues affecting oil prices, but you might as well call it "air out of the bubble" rather than anything.

Here are today's unofficial closing bell levels:
DJIA 11,283.74 (-42.58)
S&P500 1,249.01 (-11.30)
NASDAQ 2,285.17 (-25.79)
10YR T-NOTE 3.9720% (+0.024%)
52-WEEK LOWS
TOP ANALYST UPGRADES
TOP ANALYST DOWNGRADES

Humana Inc. (NYSE: HUM) sent most health insurers higher after it posted $1.24 EPS versus a prior guidance of $1.15 to $1.20 EPS and above $1.18 estimates. Shares were up over 5% to $47.00 in today's final minutes.

"Normally, you hear that in the event of a recession, defensive sectors such as healthcare and consumer staples are the best place to be," note technical experts Dr. Marvin Appel and Gerald Appel in their Systems & Forecasts. But are they?

"The reason these are called 'defensive' is that consumer demand for these goods does not shrink by very much during recessions. As such, corporate profits should hold up better than average. Consumer staples has the added advantage of being a sector with below-average volatility generally.

"Data from Ned Davis Research confirms this bit of investing folklore. Briefly, the two best-performing sectors in the six and 12 month periods following the onset of the five recessions from 1973 through 2001 were healthcare and consumer staples. So far, so good.

"The problem is that just because the performance of these sectors during recessions has been better than other areas of the S&P, that does not mean that their returns have been very good.

Yesterday was a difficult trading session for the managed healthcare group, with industry giant WellPoint Inc. (NYSE: WLP) cutting its 2008 profit forecast, blaming higher claims expense and the weak market conditions. Today is another tough day, with health care companies taking another hit on pressure from Humana Inc. (NYSE: HUM), which warned about lower-than-expected first quarter and full year earnings results.

Blaming increased prescription expenses, the second largest seller of Medicare drugs cut its first-quarter earnings outlook to a range of 44 to 46 cents a share against its previous prior guidance of 80 to 85 cents a share. Analysts, on average, expected the health insurer show higher first-quarter earnings of 78 cents, according to Thomson Financial.

The company also projected full-year earnings between $4.00 and $4.25 per share, down from a previous forecast of $5.35 to $5.55. Humana's estimates were below analysts' expectations for full-year earnings of $5.47per share.

What's the new president - - Republican or Democrat -- likely to face after taking the oath of office in 2009?

Daunting fiscal problems -- and right at a time when Congress may have to consider more fiscal stimulus to jump-start the U.S. economy, one economist observed.

The biggest problem, economist Glen Langan said, will be the federal government's budget deficit. The United States is on-track to record a $200 billion deficit in Fiscal 2009 and a $241 billion in Fiscal 2010 -- and that's if the U.S. economy doesn't fall into a recession, Langan said, citing Congressional Budget Office data.

"The baseline CBO projections present a large budgetary task for the new president, but by itself it's not an impossible one, absent a major recession. The problem is there's no money available to tackle any other problems, including ones a Democratic president would address -- health care, energy policy, education and infrastructure. And don't forget the Iraq War, anti-terrorism efforts, and potential mortgage assistance programs," Langan said. "If there aren't changes to the tax code, given the current revenue structure and tax rates,to say the next president's hands are tied regarding new programs, would be an understatement."

Google (NASDAQ: GOOG) will enter the medical records business with The Cleveland Clinic, one of the top hospitals in the world.

According to The Wall Street Journal (subscription required), "Under the pilot, patients who already use Cleveland Clinic's personal health record system can securely share medical information such as prescriptions, conditions and allergies between the Cleveland Clinic system and a Google health-profile online."

The program is a good idea. Patients' records currently are tied to the data held by doctors and hospitals. If a patient wants to access his data or share it with other health-care providers, he has to request and wait, sometimes for days, to get information that could be very useful in his treatment.

The Google program may ruffle feathers of both doctors and health-care software management companies. Doctors are concerned with keeping records private. Once they are stored and accessible on the web this will be harder to control. Software companies that supply programs for managing medical records may find that the Google system competes with some of their business based on organizing and storing patient information.

But, for the patient who now has new-found access to his own data, the program gives him power over his own medical data.

Douglas A. McIntyre is an editor at 247wallst.com.

Health care is a very serious matter, and polling indicates that Americans consider it of the utmost importance, rating it right after the economy in general, and above the Iraq war and homeland security.

It is strange to me then that 'television,' while not showing up in national polls, ranks higher then health care as a priority when it comes to household spending. If you believe the numbers in the news, 99% of households own televisions but only 84% have health insurance in any form.

Certainly cost and availability are the screaming issues of the day. However, value judgments also play a roll and I believe that whatever solutions are proposed, individual choice and responsibility should remain of paramount importance and that maintaining competition in the market place remain a principal goal.

Wal-Mart (NYSE: WMT) wants to be your doctor -- sort of. The company plans to open hundreds of new clinics in its stores. They will be co-branded with medical groups and hospitals and some will be staffed by nurse practitioners.

"We have learned that people are willing to receive their health care from the front of a store or the back of a drugstore," Dr. John Agwunobi, a medical doctor who is a Wal-Mart senior vice president, told The New York TImes.

Several drug store chains have already gotten into the business, so Wal-Mart is not alone. Since many Wal-Mart customers do not have health insurance, the retailer may be able to take a big piece of the market with low pricing.

Wal-Mart and its partners do need to be concerned with malpractice issues. One reason medical costs are so high is large malpractice insurance rates. Some patients who sue doctors and hospitals do get large awards.

A huge company like Wal-Mart is a ready-made target for people unhappy with a poor treatment result.

Douglass McIntyre is an editor at 247wallst.com.

In the midst of all the bad news it's hard to imagine the stock market ending the year higher than it started. However, that is entirely possible and probably much better than a 50/50 bet. If you want to play it safe consider buying into an index fund or exchange traded funds (ETFs) instead of banking on individual stocks.

For broad coverage you cannot beat the Vanguard Total Stock Market or the Total International Stock funds with the lowest fees and longest history in this area. I think it has also been generally accepted investing strategy over the last few decades that in bearish markets there is a run to quality and "guns and butter" stocks. If you were to follow this old adage you would be considering three sectors, healthcare, defense and consumer staples.

Mutual funds and ETFs (with less history) are less volatile and offer greater diversification than most investors could achieve, and at much lower cost. If you dollar cost average over the next few months you should also be able to smooth out some bumps in the current market.

When the political machine goes to work to juice the economy the market has most often responded positively. That does not mean it's smart for the country, but since when is a politicians first thought about the country.

Pfizer (NYSE: PFE) shares are slightly cheaper now than a decade ago, even though the company's per-share profits are more than 70% higher. The stock is unloved for a reason: Pfizer, like many drug makers at the moment, is finding it difficult to develop new medicines.

The company's biggest seller, Lipitor for lowering cholesterol, faces the loss of patent protection in 2011. Two of Pfizer's past hits, Zoloft for depression and Norvasc for high blood pressure, are already losing sales to generic competitors. Last year, a promising inhaled insulin flopped in the marketplace. The year before, a drug that raises levels of so-called good cholesterol proved too risky, and research was halted.

And Pfizer isn't alone. Last year, the Food and Drug Administration approved just 16 first-of-its-kind drugs, a 20-year low.

All that said, I think the stock warrants a purchase at today's price for five reasons.

The Coca-Cola Company (NYSE: KO) should not have a problem selling Coke, even in a recession. It traded up to $65.31 from 52-week low of $45.56.

The Southern Company (NYSE: SO) is an electrical utility with safe yield of 4.1%. It moved up to $40.52 from 52-week low of $33.16.

Abbott Laboratories (NYSE: ABT). Healthcare seems like safe haven. ABT traded up to $60.29 from 52-week low at $49.58.

Genzyme Corporation (NASDAQ: GENZ). Analysts say sales should be strong for several years. Stock was up to $79.70 from 52-week low of $58.71.

Douglas A. McIntyre is an editor at 247wallst.com.

Wal-Mart (NYSE: WMT) is insuring more of its workers. It does not seem to want to advertise that fact, but it is true nonetheless. According to The New York Times, "Wal-Mart, the nation's largest private employer, provides insurance to 100,000 more workers than it did just three years ago -- and it is now easier for many to sign up for health care at Wal-Mart than at its rival Target (NYSE:TGT), whose reputation glows in comparison."

The world's largest retailer is still offering less than half of its US workers healthcare benefits. The company plans more improvements with all workers being able to pick from a group of different plans by next year.

The move does not come without some potential risk for shareholders. Wal-Mart's margins in the US are already pinched by slow same-store sales, high fuel costs, and a slowing economy. While insuring more people may be the right thing to do, over time it may not help the firm's share price.

Being a Wal-Mart worker may be getting better than being an investor.

Douglas A. McIntyre is an editor at 247wallst.com